Evon Medics

Evon Medics operates at the intersection of neurotechnology, digital therapeutics, medical devices, and clinical research. Its focus differs from conventional cognitive-training applications because the company combines MemoryDriver’s navigation exercises with olfactory and chemosensory interventions intended to engage brain pathways associated with cognition, addiction, and pain. The portfolio also includes COAT, CBOT, CBOT-P, EDITOR, and EMRAST, giving the company exposure to both therapeutic and diagnostic use cases. Its stated approach is largely non-invasive and home-based, with supporting infrastructure that includes mobile applications, a clinical cloud portal, and remote-monitoring capabilities. The company’s $12.1 million in recorded funding has come through five grants, primarily from National Institutes of Health agencies, rather than disclosed venture rounds. That financing profile suggests a research-led position with emphasis on federally supported validation. Its main market challenge is converting promising research and patents into regulated, reimbursed, and widely adopted products.

Evon Medics’ trajectory shows a progression from federally funded research toward a broader product portfolio and more visible digital-product activity. Founded in 2013, the company recorded five grants totaling $12,070,064 between 2018 and 2023. Funding accelerated in 2021 and 2022, including a $2,641,180 National Institute on Aging grant, a $2.8 million National Institute on Drug Abuse grant, and a $3,229,999 National Institute of Neurological Disorders and Stroke grant. A further $2,948,885 National Institute on Aging grant followed on May 2, 2023. The product set now spans cognitive support, Alzheimer’s-related diagnostics, substance-use-disorder applications, chronic pain, and remote disease management. The Sep 15, 2026 MemoryDriver relaunch represents a second inflection point, moving the company toward direct user engagement through a free application and national challenge. Growth remains difficult to quantify: the company is listed in the 11–50 employee range, has one featured current position, and has no reported hiring program or disclosed commercial revenue.